한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제27권4호
  • /
  • Pages.380-387
  • /
  • 2023
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Clinicopathological characteristics of extrahepatic biliary neuroendocrine neoplasms in the gallbladder, extrahepatic biliary tract, and ampulla of Vater: A single-center cross-sectional study

  • Young Mok Park (Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Hyung Il Seo (Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Byeong Gwan Noh (Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Suk Kim (Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Seung Baek Hong (Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Nam Kyung Lee (Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Dong Uk Kim (Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Sung Yong Han (Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine)
  • 투고 : 2023.03.28
  • 심사 : 2023.06.06
  • 발행 : 2023.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: In 2019, the grading and staging system for neuroendocrine neoplasms (NENs) was significantly changed. In this study, we report the clinicopathological characteristics and surgical outcomes of patients with extrahepatic biliary NENs who underwent curative resection with or without adjuvant treatment. Methods: We retrospectively reviewed a database of 16 patients who developed NENs, neuroendocrine carcinoma (NEC), and mixed endocrine non-endocrine neoplasms (MiNENs) after curative resection. Among them, eight patients had ampulla of Vater (AoV) tumors, and eight patients had non-AoV tumors. Results: G1 and G2 were more frequently observed in the AoV group than in the non-AoV group (12.5% and 62.5%, respectively). In contrast, NEC and MiNEN were more common in the non-AoV group (50.0%). High Ki-67 index (> 20%) and perineural invasion (PNI) were more frequently observed in the non-AoV group. Advanced age (> 65 years), mitotic count > 20 per 2 mm2, and Ki-67 index > 20% were strongly correlated with patient survival (p = 0.018, 0.009, and 0.044, respectively). Advanced age (> 65 years) and mitotic count > 20 per 2 mm2 were significantly correlated with disease recurrence (p = 0.033 and 0.010, respectively). Conclusions: AoV and non-AoV tumors had significant differences in the histologic grade, Ki67, and PNI. Patients with non-AoV tumors had an increased risk for survival and recurrence than those in the AoV group. For extrahepatic biliary NENs, early detection of tumors, adequate surgery, and aggressive adjuvant treatment for high-risk patients are important to achieve long-term survival and prevent disease recurrence.

키워드

참고문헌

  1. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse endocrine system. Curr Opin Oncol 2008;20:1-12.  https://doi.org/10.1097/CCO.0b013e3282f1c595
  2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoids tumors. Cancer 1997;79:813-829.  https://doi.org/10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2
  3. Kim J, Lee WJ, Lee SH, Lee KB, Ryu JK, Kim YT, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. Dig Liver Dis 2011;43:965-970.  https://doi.org/10.1016/j.dld.2011.07.010
  4. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO Classification of tumours of the digestive system. Histopathology 2020;76:182-188.  https://doi.org/10.1111/his.13975
  5. de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, et al. Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms. Neuroendocrinology 2017;105:412-425.  https://doi.org/10.1159/000475527
  6. Eltawil KM, Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol 2010;44:687-695.  https://doi.org/10.1097/MCG.0b013e3181d7a6d4
  7. Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Kusumi T, Sato F. et al. In vivo chemotherapeutic profile of human gallbladder small cell carcinoma. Biomed Res 2008;29:251-256.  https://doi.org/10.2220/biomedres.29.251
  8. Jun SR, Lee JM, Han JK, Choi BI. High-grade neuroendocrine carcinomas of the gallbladder and bile duct: report of four cases with pathological correlation. J Comput Assist Tomogr 2006;30:604-609.  https://doi.org/10.1097/00004728-200607000-00009
  9. Lane JE, Walker AN, Ayers GW, Foster JL, Williams JT. Small-cell undifferentiated carcinoma of neuroendocrine type originating in the gallbladder. Curr Surg 2002;59:495-497.  https://doi.org/10.1016/S0149-7944(02)00638-4
  10. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. [Online, 16 December, 2017]. National Comprehensive Cancer Network. 
  11. Klimstra D, Kloppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours Editorial Board, ed. Digestive system tumours WHO classification of tumours. 5th ed. IARC, 2019:16-19. 
  12. Gastrointestinal Pathology Study Group of Korean Society of Pathologists; Cho MY, Kim JM, Sohn JH, Kim MJ, Kim KM, Kim WH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012;44:157-165.  https://doi.org/10.4143/crt.2012.44.3.157
  13. Kitano M, Yoshida T, Itonaga M, Tamura T, Hatamaru K, Yamashita Y. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol 2019;54:19-32.  https://doi.org/10.1007/s00535-018-1519-2
  14. Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol 2012;13:24-34.  https://doi.org/10.1007/s11864-011-0172-2
  15. Zheng Z, Chen C, Li B, Liu H, Zhou L, Zhang H, et al. Biliary neuroendocrine neoplasms: clinical profiles, management, and analysis of prognostic factors. Front Oncol 2019;9:38. 
  16. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas 2012;41:840-844.  https://doi.org/10.1097/MPA.0b013e31823cdaa0
  17. Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine neoplasm: recent advances and controversies. Expert Rev Anticancer Ther 2019;19:1028-1050.  https://doi.org/10.1080/14737140.2019.1693893
  18. Jayant M, Punia R, Kaushik R, Sharma R, Sachdev A, Nadkarni NK, et al. Neuroendocrine tumors of the ampulla of Vater: presentation, pathology and prognosis: presentation. JOP 2012;13:263-267. 
  19. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010;17:2427-2443.  https://doi.org/10.1245/s10434-010-1006-3
  20. Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI. Pharmacotherapy of neuroendocrine cancers. Expert Opin Pharmacother 2008;9:2617-2626.  https://doi.org/10.1517/14656566.9.15.2617
  21. Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 2010;40:313-318. https://doi.org/10.1093/jjco/hyp173